Drying US derma revenues prompt revised Almirall guidance and 24% share decline

10 July 2017

Monday has been a painful day for Almirall (ALM: MC), Spain’s largest drugmaker, which looked set to close the day’s trading having lost a quarter of its share value.

The dermatology specialist announced a guidance update to take account of the adverse impact of market developments in US dermatology, reducing its initial estimations for total revenues, net sales and earnings before interests, tax, depreciation and amortization (EBITDA) growth for this year.

"While we view the current situation as very challenging, we remain focused on delivering our strategic goals and creating value for our stakeholders"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK